Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players

Exosomes, a category of small lipid bilayer extracellular vesicles that are naturally secreted by many cells (both healthy and diseased), carry cargo made up of proteins, lipids, DNAs, and RNAs; all of which are functional when transferred to their recipient cells. Numerous studies have demonstrated...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 2103
Main Authors Othman, Norahayu, Jamal, Rahman, Abu, Nadiah
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.09.2019
Subjects
cancer
Exosomes
immune molecules
Immunology
inflammation
tumorigenesis
immune molecules
cancer
tumorigenesis
Exosomes
inflammation
Online AccessGet full text

Cover

More Information
Summary:Exosomes, a category of small lipid bilayer extracellular vesicles that are naturally secreted by many cells (both healthy and diseased), carry cargo made up of proteins, lipids, DNAs, and RNAs; all of which are functional when transferred to their recipient cells. Numerous studies have demonstrated the powerful role that exosomes play in the mediation of cell-to-cell communication to induce a pro-tumoral environment to encourage tumor progression and survival. Recently, considerable interest has developed in regard to the role that exosomes play in immunity; with studies demonstrating the ability of exosomes to either metabolically alter immune players such as dendritic cells, T cells, macrophages, and natural killer cells. In this review, we summarize the recent literature on the function of exosomes in regulating a key process that has long been associated with the progression of cancer-inflammation and immunity.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Mallikarjun Bidarimath, Cornell University, United States; Kawaljit Kaur, University of California, Los Angeles, United States
Edited by: Fatemeh Momen-Heravi, Columbia University, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.02103